Arpida preparing for Swiss IPO

Swiss pharmaceutical company Arpida Ltd is preparing for an initial public offering. The company hopes to raise between SFr 97-119m. Deutsche Bank AG is the global coordinator, sole bookrunner and sole lead manager of the Arpida IPO. Swiss banks Julius Baer, Lombard Odier Darier Hentsch and Swissfirst will act as co-leads.Arpida, based in Muenchenstein, focuses on the discovery and development of antibiotics. Last year, Arpida acquired Combio, a Danish company with innovative chemistry technologies, in an all-share transaction, allowing Arpida to expand its candidate portfolio by leveraging Combio's 'hit to lead' chemistry technologies with Arpida's anti-infectives discovery and development expertise.A E33m funding round in June 2004 (June 2004, page 17), one of the largest private equity rounds in the Swiss healthcare sector, was placed with Swissfirst Bank, Temasek Holdings, Carnegie Fund, CITA, MVI Finance, Schroder ISF Swiss Small & Mid Cap Equity Fund, Schroder ISF Swiss Equity Fund, along with participation from existing investors Alta Berkeley, Aventic, BioMedinvest, CDC IXIS Innovation, HBM BioVentures HealthCap, 3i and Partners Group.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare